Results and Clinical Interpretation of Germline RET Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance
Open Access
- 5 November 2020
- Vol. 12 (11), 3268
- https://doi.org/10.3390/cancers12113268
Abstract
Germline RET variants are responsible for approximately 25% of medullary thyroid carcinoma (MTC) cases. Identification of RET variant carriers allows for the adoption of preventative measures which are dependent on the risk associated with the specific alteration. From 2002 to 2020, at our cancer genetics clinic, RET genetic testing was performed in 163 subjects (102 complete gene analyses and 61 targeted analyses), 72 of whom presented with MTC. A germline RET variant was identified in 31.9% of patients affected by MTC (93.8% of those having positive family history and 14.3% of clinically sporadic cases). Subsequent target testing in relatives allowed us to identify 22 asymptomatic carriers, who could undertake appropriate screening. Overall, patients with germline RET variants differed significantly from those who tested negative by family history (p < 0.001) and mean age at MTC diagnosis (44.45 vs. 56.42 years; p = 0.010), but the difference was not significant when only carriers of moderate risk variants were considered (51.78 vs. 56.42 years; p = 0.281). Out of 12 different variants detected in 49 patients, five (41.7%) were of uncertain significance (VUS). For two of these, p.Ser904Phe and p.Asp631_Leu633delinsGlu, co-segregation and genotype/phenotype analysis, matched with data from the literature, provided evidence supporting their classification in the moderate and the highest/high risk class (with a MEN2B phenotype), respectively.This publication has 55 references indexed in Scilit:
- Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic formMutation research. Reviews in mutation research, 2013
- RET Gene Abnormalities and Thyroid Disease: Who Should be Screened and WhenJournal of Clinical Research in Pediatric Endocrinology, 2013
- RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)Clinical Endocrinology, 2011
- Pathogenicity of DNA Variants and Double Mutations in Multiple Endocrine Neoplasia Type 2 and Von Hippel-Lindau SyndromeJournal of Clinical Endocrinology & Metabolism, 2010
- Medullary Thyroid Cancer: Management Guidelines of the American Thyroid AssociationThyroid®, 2009
- Prognosis of medullary thyroid carcinomaCancer, 2006
- A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET MutationsBiochemical and Biophysical Research Communications, 2000
- The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor proteinOncogene, 1999
- Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogeneOncogene, 1997
- Mutations in the RET proto-oncogene are associated with MEN 2A and FMTCHuman Molecular Genetics, 1993